RVMD - Revolution Medicines Inc
IEX Last Trade
42.7
0.900 2.108%
Share volume: 717,465
Last Updated: Fri 30 Aug 2024 09:59:58 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$41.80
0.90
2.15%
Fundamental analysis
9%
Profitability
0%
Dept financing
4%
Liquidity
75%
Performance
4%
Performance
5 Days
-2.31%
1 Month
-5.58%
3 Months
11.68%
6 Months
42.29%
1 Year
28.02%
2 Year
113.26%
Key data
Stock price
$42.70
DAY RANGE
N/A - N/A
52 WEEK RANGE
$15.44 - $48.61
52 WEEK CHANGE
$0.22
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
Company detail
CEO: Mark Goldsmith
Region: US
Website: http://revolutionmedicines.com/
Employees: 247
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://revolutionmedicines.com/
Employees: 247
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
revolution medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. we pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.
Recent news